CTLT has been the subject of several other reports. Goldman Sachs assumed coverage on Catalent in a research note on Wednesday, January 24th. They issued a buy rating and a $50.00 price objective for the company. Royal Bank of Canada set a $48.00 price target on Catalent and gave the company a buy rating in a research report on Monday, February 5th. Stephens cut Catalent from an overweight rating to an equal weight rating in a research report on Tuesday, February 6th. Zacks Investment Research upgraded Catalent from a hold rating to a buy rating and set a $48.00 price target for the company in a research report on Wednesday, January 17th. Finally, Bank of America lifted their price target on Catalent from $47.00 to $49.00 and gave the company a buy rating in a research report on Tuesday, February 6th. Six investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $45.64.
CTLT stock opened at $41.56 on Wednesday. The company has a market capitalization of $5,402.07, a price-to-earnings ratio of 25.33, a price-to-earnings-growth ratio of 2.32 and a beta of 1.54. The company has a debt-to-equity ratio of 2.66, a current ratio of 2.22 and a quick ratio of 1.78. Catalent has a 12-month low of $27.48 and a 12-month high of $47.87.
Catalent (NYSE:CTLT) last posted its quarterly earnings results on Monday, February 5th. The company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.10. Catalent had a return on equity of 23.85% and a net margin of 3.03%. The business had revenue of $606.30 million for the quarter, compared to the consensus estimate of $565.05 million. During the same quarter in the prior year, the company earned $0.27 EPS. The business’s revenue was up 25.3% compared to the same quarter last year. equities research analysts expect that Catalent will post 1.53 earnings per share for the current fiscal year.
In related news, SVP William Downie sold 9,082 shares of the business’s stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $41.80, for a total transaction of $379,627.60. Following the completion of the transaction, the senior vice president now directly owns 46,986 shares of the company’s stock, valued at approximately $1,964,014.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.70% of the stock is currently owned by insiders.
Several large investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. boosted its position in shares of Catalent by 14.8% during the 4th quarter. Meeder Asset Management Inc. now owns 9,445 shares of the company’s stock worth $388,000 after acquiring an additional 1,218 shares in the last quarter. First Bank & Trust raised its stake in Catalent by 54.2% during the 4th quarter. First Bank & Trust now owns 3,764 shares of the company’s stock valued at $155,000 after acquiring an additional 1,323 shares during the last quarter. Envestnet Asset Management Inc. raised its stake in Catalent by 5.1% during the 4th quarter. Envestnet Asset Management Inc. now owns 29,439 shares of the company’s stock valued at $1,209,000 after acquiring an additional 1,430 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of Catalent by 4.1% during the 4th quarter. SG Americas Securities LLC now owns 39,984 shares of the company’s stock worth $1,643,000 after buying an additional 1,579 shares in the last quarter. Finally, Strs Ohio raised its stake in shares of Catalent by 7.4% during the 4th quarter. Strs Ohio now owns 23,300 shares of the company’s stock worth $957,000 after buying an additional 1,600 shares in the last quarter. 99.89% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Catalent (CTLT) Upgraded by UBS to “Outperform”” was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/03/22/catalent-ctlt-upgraded-by-ubs-to-outperform.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.